 Marisa Moroney
Concepts (101)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endometrial Neoplasms | 4 | 2022 | 209 | 1.740 |
Why?
| | Wnt Signaling Pathway | 2 | 2021 | 210 | 1.130 |
Why?
| | beta Catenin | 3 | 2022 | 253 | 1.110 |
Why?
| | Ovarian Neoplasms | 4 | 2020 | 592 | 0.960 |
Why?
| | Uterine Cervical Neoplasms | 3 | 2022 | 270 | 0.780 |
Why?
| | Carcinoma, Endometrioid | 2 | 2022 | 51 | 0.740 |
Why?
| | Wnt Proteins | 1 | 2021 | 133 | 0.630 |
Why?
| | Surgical Oncology | 1 | 2019 | 30 | 0.570 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2018 | 76 | 0.500 |
Why?
| | Lymph Nodes | 1 | 2018 | 502 | 0.440 |
Why?
| | Mutation | 4 | 2022 | 4104 | 0.410 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2022 | 1148 | 0.390 |
Why?
| | Palliative Care | 1 | 2019 | 1012 | 0.320 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2021 | 1462 | 0.210 |
Why?
| | Enoxaparin | 1 | 2024 | 67 | 0.200 |
Why?
| | Neoplasms | 1 | 2019 | 2887 | 0.200 |
Why?
| | Genital Neoplasms, Female | 1 | 2024 | 99 | 0.190 |
Why?
| | Pyridones | 1 | 2024 | 200 | 0.180 |
Why?
| | Neoplasm Grading | 2 | 2022 | 310 | 0.180 |
Why?
| | Treatment Adherence and Compliance | 1 | 2021 | 27 | 0.170 |
Why?
| | Wnt4 Protein | 1 | 2021 | 20 | 0.170 |
Why?
| | Genital Diseases, Female | 1 | 2021 | 31 | 0.170 |
Why?
| | Genitalia, Female | 1 | 2021 | 42 | 0.170 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2021 | 44 | 0.170 |
Why?
| | Indazoles | 1 | 2021 | 83 | 0.160 |
Why?
| | Pyrazoles | 1 | 2024 | 510 | 0.160 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2020 | 67 | 0.160 |
Why?
| | Imidazoles | 1 | 2021 | 254 | 0.150 |
Why?
| | Disease Susceptibility | 1 | 2021 | 348 | 0.150 |
Why?
| | DNA Polymerase II | 1 | 2019 | 35 | 0.150 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 36 | 0.150 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2020 | 425 | 0.150 |
Why?
| | Microsatellite Instability | 1 | 2019 | 54 | 0.140 |
Why?
| | Women's Health | 1 | 2021 | 310 | 0.140 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2022 | 533 | 0.140 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 109 | 0.140 |
Why?
| | Molecular Targeted Therapy | 1 | 2021 | 434 | 0.140 |
Why?
| | Cell Survival | 1 | 2021 | 1099 | 0.130 |
Why?
| | Frozen Sections | 1 | 2018 | 24 | 0.130 |
Why?
| | Recurrence | 1 | 2021 | 1138 | 0.130 |
Why?
| | PTEN Phosphohydrolase | 1 | 2019 | 165 | 0.130 |
Why?
| | Neoplasm Metastasis | 1 | 2020 | 697 | 0.130 |
Why?
| | Neoadjuvant Therapy | 1 | 2020 | 463 | 0.130 |
Why?
| | Female | 11 | 2024 | 78605 | 0.130 |
Why?
| | Disease Management | 1 | 2021 | 647 | 0.130 |
Why?
| | Pyridines | 1 | 2021 | 605 | 0.120 |
Why?
| | Lymph Node Excision | 1 | 2018 | 174 | 0.120 |
Why?
| | Tumor Microenvironment | 1 | 2020 | 736 | 0.120 |
Why?
| | Biomarkers, Tumor | 2 | 2022 | 1325 | 0.110 |
Why?
| | Adenocarcinoma | 1 | 2022 | 931 | 0.110 |
Why?
| | Neoplasm Staging | 1 | 2019 | 1470 | 0.110 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2020 | 886 | 0.110 |
Why?
| | Humans | 12 | 2024 | 145307 | 0.110 |
Why?
| | Healthcare Disparities | 1 | 2021 | 736 | 0.100 |
Why?
| | Patient Education as Topic | 1 | 2019 | 782 | 0.100 |
Why?
| | Middle Aged | 6 | 2024 | 36021 | 0.100 |
Why?
| | Cell Line, Tumor | 1 | 2021 | 3560 | 0.100 |
Why?
| | Patient Care Team | 1 | 2019 | 692 | 0.100 |
Why?
| | Membrane Proteins | 1 | 2019 | 1169 | 0.090 |
Why?
| | Disease Progression | 1 | 2020 | 2855 | 0.090 |
Why?
| | Antineoplastic Agents | 2 | 2020 | 2202 | 0.090 |
Why?
| | Postoperative Complications | 1 | 2024 | 2938 | 0.090 |
Why?
| | Case-Control Studies | 1 | 2019 | 3613 | 0.080 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1962 | 0.080 |
Why?
| | Retrospective Studies | 4 | 2024 | 17149 | 0.070 |
Why?
| | Inflammation | 1 | 2020 | 2881 | 0.070 |
Why?
| | Aged | 4 | 2024 | 26001 | 0.070 |
Why?
| | Quality of Life | 1 | 2019 | 3197 | 0.060 |
Why?
| | Cross-Sectional Studies | 1 | 2018 | 5883 | 0.060 |
Why?
| | Survival Rate | 2 | 2021 | 2100 | 0.060 |
Why?
| | Gynecologic Surgical Procedures | 1 | 2024 | 64 | 0.050 |
Why?
| | Prognosis | 2 | 2024 | 4310 | 0.050 |
Why?
| | Follow-Up Studies | 2 | 2024 | 5431 | 0.050 |
Why?
| | Cervix Uteri | 1 | 2022 | 51 | 0.050 |
Why?
| | Factor Xa Inhibitors | 1 | 2024 | 187 | 0.050 |
Why?
| | Adult | 3 | 2021 | 40627 | 0.040 |
Why?
| | Sex Differentiation | 1 | 2021 | 10 | 0.040 |
Why?
| | Sexual Development | 1 | 2021 | 16 | 0.040 |
Why?
| | Mammary Glands, Human | 1 | 2021 | 67 | 0.040 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2020 | 52 | 0.040 |
Why?
| | Uterus | 1 | 2021 | 226 | 0.040 |
Why?
| | Venous Thromboembolism | 1 | 2024 | 324 | 0.040 |
Why?
| | Anticoagulants | 1 | 2024 | 726 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2021 | 8295 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1268 | 0.030 |
Why?
| | Survival Analysis | 1 | 2020 | 1386 | 0.030 |
Why?
| | Guideline Adherence | 1 | 2021 | 589 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2021 | 1327 | 0.030 |
Why?
| | Quality of Health Care | 1 | 2021 | 696 | 0.030 |
Why?
| | Databases, Factual | 1 | 2021 | 1488 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2021 | 2152 | 0.020 |
Why?
| | Cohort Studies | 1 | 2021 | 5982 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2022 | 3888 | 0.020 |
Why?
| | Breast Neoplasms | 1 | 2021 | 2464 | 0.020 |
Why?
| | Pregnancy | 1 | 2021 | 7208 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2020 | 11731 | 0.010 |
Why?
| | Young Adult | 1 | 2021 | 14163 | 0.010 |
Why?
| | Mice | 1 | 2021 | 18397 | 0.010 |
Why?
| | United States | 1 | 2021 | 16051 | 0.010 |
Why?
| | Adolescent | 1 | 2021 | 22507 | 0.010 |
Why?
| | Animals | 1 | 2021 | 38180 | 0.010 |
Why?
|
|
Moroney's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|